National Cancer Center Hospital East Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2016
NCT02851004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Takayuki Yoshino

Active Ingredients

Drugs in Phase 2 Trials (3)

napabucasin (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (2 trials)

Drugs in Phase 1 Trials (1)

Telomelysin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4